Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS)
| Market Cap | $897.52M+21.3% |
| Revenue (ttm) | $0 |
| Net Income | -$64.31M-326.6% |
| EPS | -$0.74-39.6% |
| Shares Out | 84.35M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 625,302 |
| Open | $10.56 |
| Previous Close | $10.62 |
| Day's Range | $10.24 - $10.76 |
| 52-Week Range | $6.39 - $26.95 |
| Beta | 0.86 |
| Analysts | Buy |
| Price Target | $27.00(+153.76%) |
| Earnings Date | Mar 11, 2027 |
About CRVS
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Corvus Pharmaceuticals, Inc. Stock Analysis — InsiderScore
Corvus Pharmaceuticals, Inc. scored higher than 73% of companies evaluated by InsiderBuying, and ranked 20th out of 99 stocks in the biotech sector.
Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.
Insiders at Corvus Pharmaceuticals, Inc. bought $50.5K of stock across 4 purchases in the last 90 days, the largest of them $34.4K.
The average purchase added about 14% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.
1 of these purchases was made by someone who held no stock at all beforehand — going from nothing to a position is the strongest form of this signal.
This category carries 35% of the Insider Score.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Mar 11, 2027Earnings report
$CRVS stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in CRVS holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by CRVS's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
CRVS Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New CRVS patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to CRVS from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in CRVS
| VTIVanguard Morningstar Total Stock Market ETF | $27.73M |
| XBIState Street SPDR S&P Biotech ETF | $20.32M |
| IWMiShares Russell 2000 ETF | $18.85M |
| VXFVanguard Extended Market ETF | $9.65M |
| IWOiShares Russell 2000 Growth ETF | $6.89M |
| IBBiShares Biotechnology ETF | $5.66M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from CRVS’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| LFSC | F/M Emerald Life Sciences Innovation ETF | 1.53% |
| CANC | Tema Oncology ETF | 0.76% |
| BBC | Virtus Biotech Clinical Trials ETF | 0.71% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 0.63% |
| SBIO | ALPS Medical Breakthroughs ETF | 0.58% |
| TMED | T. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF | 0.45% |
| TDNA | T. Rowe Price Biotech ETF | 0.39% |
| SURI | Simplify Propel Opportunities ETF | 0.37% |
| XBI | State Street SPDR S&P Biotech ETF | 0.19% |
| IWC | iShares Micro-Cap ETF | 0.18% |
| OPTZ | Optimize Strategy Index ETF | 0.14% |
| VFMO | Vanguard U.S. Momentum Factor ETF | 0.09% |
Weight is the stock’s share of each fund’s holdings.